Private Advisor Group LLC Has $1.46 Million Stock Holdings in TransMedics Group, Inc. (NASDAQ:TMDX)

Private Advisor Group LLC trimmed its holdings in shares of TransMedics Group, Inc. (NASDAQ:TMDX) by 7.4% in the third quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The fund owned 9,278 shares of the company’s stock after selling 739 shares during the period. Private Advisor Group LLC’s holdings in TransMedics Group were worth $1,456,000 at the end of the most recent quarter.

Other large investors also recently modified their holdings of the company. Vanguard Group Inc. boosted its stake in shares of TransMedics Group by 2.8% during the 4th quarter. Vanguard Group Inc. now owns 1,865,115 shares of the company’s stock worth $147,214,000 after buying an additional 50,673 shares during the last quarter. Allspring Global Investments Holdings LLC lifted its stake in TransMedics Group by 5.3% in the 3rd quarter. Allspring Global Investments Holdings LLC now owns 599,116 shares of the company’s stock valued at $94,061,000 after purchasing an additional 30,092 shares during the last quarter. Deerfield Management Company L.P. Series C acquired a new stake in TransMedics Group in the 2nd quarter valued at about $1,400,000. Handelsbanken Fonder AB lifted its stake in TransMedics Group by 657.6% in the 3rd quarter. Handelsbanken Fonder AB now owns 64,400 shares of the company’s stock valued at $10,111,000 after purchasing an additional 55,900 shares during the last quarter. Finally, Russell Investments Group Ltd. lifted its stake in TransMedics Group by 337,462.5% in the 1st quarter. Russell Investments Group Ltd. now owns 27,005 shares of the company’s stock valued at $1,997,000 after purchasing an additional 26,997 shares during the last quarter. 99.67% of the stock is currently owned by institutional investors and hedge funds.

Analyst Ratings Changes

Several brokerages recently issued reports on TMDX. Piper Sandler reiterated an “overweight” rating and issued a $180.00 target price on shares of TransMedics Group in a research note on Tuesday. Needham & Company LLC cut their target price on shares of TransMedics Group from $208.00 to $109.00 and set a “buy” rating for the company in a research note on Tuesday. Oppenheimer cut their target price on shares of TransMedics Group from $200.00 to $125.00 and set an “outperform” rating for the company in a research note on Tuesday. Morgan Stanley raised their target price on shares of TransMedics Group from $104.00 to $145.00 and gave the company an “equal weight” rating in a research note on Monday, July 15th. Finally, Canaccord Genuity Group lowered their price target on shares of TransMedics Group from $169.00 to $109.00 and set a “buy” rating on the stock in a report on Tuesday. One equities research analyst has rated the stock with a hold rating, nine have given a buy rating and one has issued a strong buy rating to the company’s stock. Based on data from MarketBeat, the company has a consensus rating of “Buy” and a consensus target price of $144.80.

TransMedics Group Stock Down 7.4 %

Shares of TMDX opened at $81.92 on Thursday. TransMedics Group, Inc. has a 12 month low of $36.42 and a 12 month high of $177.37. The firm’s 50 day moving average is $144.20 and its 200-day moving average is $139.76. The stock has a market capitalization of $2.73 billion, a PE ratio of 87.15 and a beta of 1.99. The company has a current ratio of 9.37, a quick ratio of 8.48 and a debt-to-equity ratio of 2.67.

TransMedics Group (NASDAQ:TMDX) last announced its earnings results on Monday, October 28th. The company reported $0.12 EPS for the quarter, missing the consensus estimate of $0.29 by ($0.17). TransMedics Group had a return on equity of 15.98% and a net margin of 0.84%. The business had revenue of $108.76 million for the quarter, compared to the consensus estimate of $115.00 million. During the same period in the prior year, the business posted ($0.12) earnings per share. The firm’s revenue for the quarter was up 63.7% compared to the same quarter last year. Equities research analysts forecast that TransMedics Group, Inc. will post 1.22 EPS for the current year.

Insider Transactions at TransMedics Group

In other news, CEO Waleed H. Hassanein sold 8,625 shares of the firm’s stock in a transaction that occurred on Tuesday, October 15th. The shares were sold at an average price of $132.71, for a total transaction of $1,144,623.75. Following the transaction, the chief executive officer now directly owns 61,643 shares of the company’s stock, valued at approximately $8,180,642.53. This trade represents a 0.00 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this hyperlink. In related news, Director Edward M. Basile sold 6,750 shares of TransMedics Group stock in a transaction that occurred on Tuesday, August 6th. The shares were sold at an average price of $149.96, for a total value of $1,012,230.00. Following the transaction, the director now directly owns 732 shares of the company’s stock, valued at $109,770.72. This trade represents a 0.00 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is available through this link. Also, CEO Waleed H. Hassanein sold 8,625 shares of TransMedics Group stock in a transaction that occurred on Tuesday, October 15th. The shares were sold at an average price of $132.71, for a total transaction of $1,144,623.75. Following the completion of the transaction, the chief executive officer now directly owns 61,643 shares in the company, valued at $8,180,642.53. This trade represents a 0.00 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last ninety days, insiders have sold 61,247 shares of company stock valued at $9,518,181. 7.00% of the stock is currently owned by company insiders.

TransMedics Group Profile

TransMedics Group, Inc, a commercial-stage medical technology company, engages in transforming organ transplant therapy for end-stage organ failure patients in the United States and internationally. The company offers Organ Care System (OCS), a portable organ perfusion, optimization, and monitoring system that utilizes its proprietary and customized technology to replicate near-physiologic conditions for donor organs outside of the human body.